Skip to main content
Premium Trial:

Request an Annual Quote

Despite Revenue Growth, Invitrogen Stock Down 11 Percent on Profit Decline

NEW YORK, Oct. 28 (GenomeWeb News) - Shares in Invitrogen skidded 11.5 percent, or $8.17, at $62.61, in mid-afternoon trading after the company reported a profit decline in the third-quarter.


GenomeWeb News reported this morning that Invitrogen's third quarter revenues increased 13 percent over last year. However, a non-cash charge of around $5.2 million related to its recent acquisition of Dynal Biotech contributed to a 15 percent decrease in net income.


Research firm William Blair downgraded the stock from "outperform" to "market perform" today.


The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.